Massachusetts General HospitalBoston, Massachusetts, United States
Seres Therapeutics (Research Grant or Support)
19 - The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
On Demand